about

  A scientist by trade, Adam has a PhD in cancer biology from Oxford University and a executive MBA from Edinburgh. After a decade in R&D at AstraZeneca, Applied Biosystems & Lab901, Adam has spent the last 15 years in marketing & commercial roles developing market and product strategy for the likes of Agilent, Merck-BioReliance & Symbiosis.

  A senior leader in technology and life science industries with a broad range of experience across both start up, SMEs and large multinational technology companies.  Currently CTO at Reactec Ltd, a safety tech IoT business and an active angel investor, Leif has helped both establish Lentitek and guide it throughout its journey.

With over 50 research publications and more than £7million in grant funding, John has built enormous academic and practical expertise in lentivirus vector design and production for clinical applications.  John established and directs the molecular interventions research group in the UCL Division of Surgery, a team developing gene therapy technologies for diseases with a severe unmet need.

 Andy has pursued a successful 25 year career across the biologics and cell & gene therapy space.  With commercial leadership roles in entrepreneurial start-ups like BioOutsource, where he was a co-founder and investor, to established international players such as AGC Biologics. More recently, Andy has been VP, Head of BD for Oxford Biomedica’s CDMO business, Chief Business Officer at Ascend GCTX and Chief Commercial Officer at Pluri CDMO. 

  Emily is one of the newest member of the Lentitek team having joined in Oct 24. She has a fantastic foundation in lentiviral vector design having completed a PhD from Manchester that involved a collaboration and placement at GSK with the lentivirus development group. Prior to joining Lentitek, Emily led vector development at Autolus, the UK’s leading

CAR-T developer.

Callum holds a PhD from the University of Cambridge, where he focused on virus–host interactions. Prior to joining Lentitek, he gained industry experience at leading biotech companies including Cell Guidance Systems and bit.bio. With a broad skill set and deep expertise in molecular and cell biology, Callum now leads technology development at Lentitek. 

Fabian holds an MSc in Biotechnology from the University of Portsmouth and brings over five years of industrial biopharma experience from roles at Lonza and Rentschler. His background spans downstream processing and analytical development, where he led efforts to establish and expand analytical capabilities for gene therapies. Fabian joins Lentitek as a Vector Development Scientist, bringing a broad and practical understanding of bioprocessing and analytics to the team.